替吉奥单药与替吉奥联合奥沙利铂在胃癌术后辅助化疗中的临床疗效观察  

Clinical Effective Observation of S-1 versus S-1 Plusoxaliplatin Program in Adjuvant Chemotherapy of Postoperative Gastric Cancer

作　　者：黄露迷[1] 冀晓辉[1] 王春梅[1] 王东林[1] 李代蓉[1] 

机构地区：[1]重庆市肿瘤研究所肿瘤内科,重庆400030

出　　处：《中国医药指南》2016年第36期1-3,共3页Guide of China Medicine

摘　　要：目的比较替吉奥单药与替吉奥联合奥沙利铂方案在胃癌术后（ⅢA～ⅢC期）辅助化疗中的疗效和安全性。方法回顾性分析2009年10月至2014年3月该院收治的90例胃癌患者的临床资料,分为单药组（替吉奥单药）及联合组（替吉奥联合奥沙利铂）。结果单药组与联合组的中位肿瘤进展时间分别为8.62个月和8.23个月,1年无复发生存率分别为27.3%和28.6%,两组比较差异无统计学意义（P〉0.05）。两组的不良反应主要为骨髓抑制、胃肠道反应、口腔黏膜炎、末梢神经毒性及肝肾功能损害。联合组骨髓抑制、胃肠道反应明显高于单药组,差异有统计学意义（P〈0.05）。结论替吉奥单药与替吉奥联合奥沙利铂在胃癌术后Ⅲ期治疗中疗效相当,但单药组患者耐受更好。Objective To investigate the efficacy and safety of S-1 versus S-1 plusoxaliplatin program in the adjuvant chemotherapy in the patients with postoperative gastric cancer（stage Ⅲ）. Methods The clinical data in 90 patients with postoperative gastric cancer, treated with S-1 or S-1 plusoxaliplatin in our hospital from October 2009 to March 2014 were retrospectively analyzed. Results Median time to progression of the S-1 group and the S-1 plusoxaliplatin group were 8.62 months vs 8.23 months. The 1 year recurrence free survival（RFS）of the two group were 27.3% vs 28.6%. There were no statistically significant differences between the two groups（P〉0.05）.The mainly adverse reactions in the two groups were mye Iosuppression, gastrointestinal reactions, mucositis, peripheral nerve toxicity, hepatic and renal function damage. The occurrence rate of myeiosuppression and gastrointestinal reactions in the S-1 plusoxaliplatin group was significantly higher than that in the S-1 group（P〈0.05）. Conclusion S-1 and S-1 plus oxaliplatin in postoperative gastric cancer（stage Ⅲ） treatment curative effect quite, with S-1 group having better tolerance.

关 键 词：胃癌 化疗 辅助 替吉奥 

分 类 号：R735.2[医药卫生—肿瘤]